Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
39
PCRX.V Quote, Financials, Valuation and Earnings
Last price:
$0.42
Seasonality move
:
95.83%
Day range:
$0.41 - $0.42
52-week range:
$0.40 - $0.66
Dividend yield:
0%
P/E ratio:
280.00x
P/S ratio:
2.85x
P/B ratio:
1.67x
Volume:
106.1K
Avg. volume:
219K
1-year change:
-31.15%
Market cap:
$50.1M
Revenue:
$5.8M
EPS (TTM):
$0.00
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, PharmaCorp Rx, Inc. has -- downside to fair value with a price target of -- per share.
PCRX.V vs. S&P 500
-
Over the past 5 trading days, PharmaCorp Rx, Inc. has overperformed the S&P 500 by 1.03% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
PharmaCorp Rx, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PharmaCorp Rx, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter PharmaCorp Rx, Inc. reported revenues of $4.8M.
Earnings Growth
-
PharmaCorp Rx, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter PharmaCorp Rx, Inc. reported earnings per share of -$0.00.
Enterprise value:
49.6M
EV / Invested capital:
1.44x
Price / LTM sales:
2.85x
EV / EBIT:
155.02x
EV / Revenue:
2.82x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-90.09x
Price / Operating cash flow:
124.13x
Enterprise value / EBITDA:
90.71x
Gross Profit (TTM):
$2.5M
Return On Assets:
0.51%
Net Income Margin (TTM):
1.04%
Return On Equity:
0.6%
Return On Invested Capital:
0.57%
Operating Margin:
-10.39%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | $1.4M | $17.6M | $1.1M | $4.8M | |
| Gross Profit | -- | -$764.3K | $2.5M | -$755.9K | $403.2K | |
| Operating Income | -$359.8K | -$2.2M | -$243.2K | -$1.1M | -$498.8K | |
| EBITDA | -$359.8K | -$2.1M | $546.8K | -$1M | -$276.5K | |
| Diluted EPS | -$0.01 | -$0.04 | $0.00 | -$0.01 | -$0.00 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $2.7M | $2.5M | $27.3M | $8.5M | |
| Total Assets | -- | $2.7M | $2.5M | $32.1M | $39.7M | |
| Current Liabilities | -- | $8.2K | $41.2K | $640.5K | $3.3M | |
| Total Liabilities | -- | $8.2K | $41.2K | $2M | $9.5M | |
| Total Equity | -- | $2.7M | $2.5M | $30.1M | $30.2M | |
| Total Debt | -- | -- | -- | $989.7K | $4.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$223.8K | -$1.3M | $1.6M | -$642.9K | $550.3K | |
| Cash From Investing | -- | -$2M | -$26.2M | -$2.1M | -$8.2M | |
| Cash From Financing | $27.8K | $27.4M | $2.9M | $7.6M | $3.1M | |
| Free Cash Flow | -$223.8K | -$1.3M | -$550.6K | -$642.9K | $537.5K | |
PCRX.V
Sector
Market Cap
$50.1M
$131.9M
Price % of 52-Week High
63.64%
72.12%
Dividend Yield
0%
0%
Shareholder Yield
-1.23%
2.32%
1-Year Price Total Return
-31.15%
-8.56%
Beta (5-Year)
--
0.258
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.42
200-day SMA
Sell
Level
$0.48
Bollinger Bands (100)
Sell
Level
0.43 - 0.49
Chaikin Money Flow
Buy
Level
75.1K
20-day SMA
Buy
Level
$0.41
Relative Strength Index (RSI14)
Sell
Level
47.68
ADX Line
Sell
Level
23.26
Williams %R
Neutral
Level
-33.3333
50-day SMA
Sell
Level
$0.45
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
956K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.5596)
Buy
CA Score
(Annual)
Level (0.9688)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.5226)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PharmaCorp Rx, Inc. operates as a capital pool company, which focuses on identifying and evaluating the assets or businesses in the pharmacy industry. It operates through the Non-Wholly Owned Pharmacies and Wholly Owned Pharmacies segments. The company was founded on September 1, 2021 and is headquartered in Hallandale Beach, FL.
Stock Forecast FAQ
In the current month, PCRX.V has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PCRX.V average analyst price target in the past 3 months is --.
-
Where Will PharmaCorp Rx, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that PharmaCorp Rx, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About PharmaCorp Rx, Inc.?
Analysts are divided on their view about PharmaCorp Rx, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PharmaCorp Rx, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is PharmaCorp Rx, Inc.'s Price Target?
The price target for PharmaCorp Rx, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PCRX.V A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PharmaCorp Rx, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PCRX.V?
You can purchase shares of PharmaCorp Rx, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PharmaCorp Rx, Inc. shares.
-
What Is The PharmaCorp Rx, Inc. Share Price Today?
PharmaCorp Rx, Inc. was last trading at $0.42 per share. This represents the most recent stock quote for PharmaCorp Rx, Inc.. Yesterday, PharmaCorp Rx, Inc. closed at $0.42 per share.
-
How To Buy PharmaCorp Rx, Inc. Stock Online?
In order to purchase PharmaCorp Rx, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get PCRX.V Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PCRX.V
Sector
P/E ratio
280.00x
16.75x
PEG ratio
--
0.13x
P/B ratio
1.67x
1.49x
Price / LTM sales
2.85x
0.51x
Growth Metrics
PCRX.V
Sector
Revenue growth
334.82%
3%
Earnings growth
58.14%
5.41%
Revenue (5-year growth)
--
3.32%
Earnings forecast
--
$0.32
Profitability
PCRX.V
Sector
Profitability FY 2024
$294.7K
$264.3M
Return on invested capital
0.57%
4.48%
Return on assets
0.51%
3.1%
Return on equity
0.6%
7.66%
Earnings Date
Last Earnings Date
Dec
16
Next Earnings Date
Dec
16
Estimated Next Earnings Date
Mar
17
Balance Sheet
PCRX.V
Sector
Total cash
$5M
$88.7M
Short term investments
--
$32.9M
Total assets
$35.2M
$1.1B
Long term debt
$4.3M
$7.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
71
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
39
SMX alert for Dec 16
SMX (Security Matters) Plc [SMX] is down 18.23% over the past day.
Sell
33
ZBIO alert for Dec 16
Zenas BioPharma, Inc. [ZBIO] is up 8.59% over the past day.
Sell
38
HUT alert for Dec 16
Hut 8 Corp. [HUT] is down 0.56% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
